AstraZeneca's biological research and development arm MedImmune has signed up to work with Inovio Pharmaceuticals on DNA-based immunotheraphy treatments for cancer and infectious diseases.

Under the terms of the deal, MedImmune will acquire exclusive rights to Inovio’s INO-3112 immunotherapy, which is in phase II and III clinical trials for cervical and head and neck cancers.